Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sign Of The Times? Micromet’s Stock Price Sluggish Despite Reasons For Optimism

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech well-funded thanks to recent deals and sees blockbuster potential in lymphoma with blinatumomab.
Advertisement

Related Content

PIPE-Line Gamble Could Let Cadence Sing A Happy Tune
PIPE-Line Gamble Could Let Cadence Sing A Happy Tune
Affymax Swings $42 Million Financing To Push Hematide
Affymax Swings $42 Million Financing To Push Hematide
Venture Capital Firms Looking For Plan B
Venture Capital Firms Looking For Plan B
Biopharma in 2008: What a Difference an Economic Crisis Makes
Micromet/MedImmune’s Blinatumomab Shows Early Promise Of BiTE Antibodies
Micromet/MedImmune’s Blinatumomab Shows Early Promise Of BiTE Antibodies
Reverse Mergers Gain Traction In Tough IPO Times

Topics

Advertisement
UsernamePublicRestriction

Register

PS067120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel